Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Enalapril Maleate

FDA-approved product (tablet, oral), marketed as Enalapril Maleate, Epaned, Epaned Kit and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Enalapril Maleate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Ventricular Dysfunction, Left

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Enalapril Maleate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Enalapril Maleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Chicken-Diet vs. Enalapril to Reduce Albuminuria

    NCT00484068 · start 2003-01

    Registered record
    Registry ID
    NCT00484068
    Conditions
    Microalbuminuria; Diabetic Nephropathy
    Interventions
    enalapril; chicken diet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-01
    Completion
    2006-06
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicroalbuminuria; Diabetic Nephropathy
    Interventionenalapril; chicken diet
    PhaseNot applicable
    Registry statusCompleted

  • Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy

    NCT00295542 · start 2000-03

    Registered record
    Registry ID
    NCT00295542
    Conditions
    Hypertension
    Interventions
    Ambulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan); beta blockers (including nebivolol, atenolol, carvedilol); diuretics (torasemide, indapamide, HTCZ) and doxazosin; Combination therapy in essential hypertension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-03
    Completion
    2009-04
    Enrolment
    3,344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmbulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) +3 more
    PhasePhase 4
    Registry statusCompleted

  • Treating Metabolic Acidosis in Chronic Kidney Disease to Prevent Adverse Kidney and Cardiovascular Outcomes

    NCT06545461 · start 1998-06-22

    Registered record
    Registry ID
    NCT06545461
    Conditions
    Chronic Kidney Diseases; Cardiovascular Diseases; Hypertension
    Interventions
    Fruits and Vegetables (F+V); Sodium Bicarbonate (NaHCO3); Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1998-06-22
    Completion
    2016-10-30
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Diseases; Cardiovascular Diseases; Hypertension
    InterventionFruits and Vegetables (F+V); Sodium Bicarbonate (NaHCO3); Usual Care
    PhaseNot applicable
    Registry statusCompleted

  • Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I

    NCT00004328 · start 1992-12

    Registered record
    Registry ID
    NCT00004328
    Conditions
    Pseudohypoaldosteronism
    Interventions
    enalapril; polystyrene sulfonate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1992-12
    Completion
    Not recorded
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudohypoaldosteronism
    Interventionenalapril; polystyrene sulfonate
    PhasePhase 2
    Registry statusCompleted

  • A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)

    NCT00882440 · start 1990-12

    Registered record
    Registry ID
    NCT00882440
    Conditions
    Hypertension
    Interventions
    losartan potassium; Placebo; Enalapril
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1990-12
    Completion
    1992-01
    Enrolment
    576

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionlosartan potassium; Placebo; Enalapril
    PhasePhase 3
    Registry statusCompleted